KeChow Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of novel small molecule drugs targeting unmet clinical needs in oncology and free radical-related diseases. Their proprietary drug candidates, including the recently approved MEK inhibitor, aim to provide effective treatment options for patients with advanced NRAS-mutant melanoma who have failed existing therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with advanced NRAS-mutant melanoma who have failed existing therapies have limited effective treatment options. There remains an unmet clinical need for novel drugs targeting this specific genetic mutation in melanoma.
Solution
KeChow Pharma is developing small molecule drugs to address unmet clinical needs in oncology, specifically focusing on NRAS-mutant melanoma. Their lead drug candidate, a MEK inhibitor, provides a targeted therapy option for patients who have progressed on or after PD-1/PD-L1 therapy. The company's pipeline consists of innovative new chemical entities designed to be best-in-class treatments for various cancers. KeChow's approach centers on creating highly selective small molecule compounds with improved drug properties and differentiated mechanisms of action.
Target Audience
The primary target audience includes patients with advanced NRAS-mutant melanoma who have failed prior therapies, as well as oncologists specializing in melanoma treatment.
Features
- MEK inhibitor specifically targets the MAPK/ERK signaling pathway in NRAS-mutant melanoma cells.
- Oral formulation for convenient administration.
- Designed for improved selectivity to minimize off-target effects.
- Addresses resistance mechanisms observed with other therapies.
- Pipeline includes other novel small molecule inhibitors targeting different oncogenic pathways.